Navigation Links
Soligenix Announces Award of $1.2 Million FDA Orphan Products Development Grant
Date:8/23/2010

PRINCETON, N.J., Aug. 23 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today that it has been awarded a three year $1.2 million clinical research grant by the Office of Orphan Products Development (OOPD) of the U.S. Food and Drug Administration (FDA) pursuant to its Orphan Products Development (OPD) Program.

The grant will be used  to defray a significant portion of the costs associated with the conduct of the Company's ongoing, confirmatory, Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host-Disease (GI GVHD).  This trial, also referred to as the SUPPORTS protocol (Sparing Unnecessary Prednisone Phase 3 orBec® Randomized Treatment Study), will enroll an estimated 166 subjects to confirm the clinically meaningful endpoints observed in previous Phase 2 and Phase 3 clinical studies. The primary endpoint in the SUPPORTS protocol is the treatment failure rate at Study Day 80. This endpoint was successfully measured as a secondary endpoint (p-value 0.005) in the Company's previous Phase 3 study as a key measure of durability following a 50-day course of treatment with orBec® (i.e., 30 days following cessation of treatment).  The Phase 3 study includes major stem cell transplantation centers in the United States, Europe and Australia, and is expected to complete in the first half of 2011.

"We are grateful to have been awarded this significant grant to support our ongoing confirmatory Phase 3 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We believe the award is a validation of the design of our Phase 3 trial and a clear indicator of the importance of orBec® and its potential application in the treatment
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
6. Soligenix Announces Publication of Positive Data Describing Protection from Mucosal and Systemic Ricin Intoxication by Intradermal RiVax™ Administration
7. Soligenix to Present at the OneMedForum Conference on Wednesday, June 30 at 2PM EDT
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 UHC has released ... use of medical devices based on cost and quality ... preference items (PPIs). The study examined utilization of PPIs—which ... supply expenses 1 —at 10 academic medical centers, focusing ... and cardiac valves. The study, begun ...
(Date:3/31/2015)... , March 31, 2015  The increasing ... applications have driven the need for automated ... automated segments are going to replace the ... This study provides the market overview, market ... key trends for the liquid handling market ...
(Date:3/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/gj8bvd/global_nuclear ... Nuclear Imaging Market 2015-2019" report to their offering. ... market to grow at a CAGR of 5.89 percent ... report, Global Nuclear Imaging market 2015-2019, has been prepared ... industry experts. The report covers the Americas, and the ...
Breaking Medicine Technology:UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 2UHC Study: Variations in Use of Physician Preference Items Affect Patient Outcomes and Costs 3Western European Liquid Handling Market 2Global Nuclear Imaging Market 2015-2019 with GE healthcare, Philips Healthcare & Siemens Healthcare Dominating 2
... Qualia Clinical Services, a highly,regarded division of ... (EDC) system to streamline and,automate clinical trials in ... "Automating our recently expanded Phase I facility with ... Biotech sponsors with top quality, real,time access to ...
... PARK, Ill., Oct. 20 Abbott has,received a ... Drug,Administration (FDA) for its New Drug Application (NDA) ... is,evaluating the FDA Complete Response Letter, will discuss ... update when appropriate., Abbott is seeking the ...
Cached Medicine Technology:Qualia Clinical Services Chooses ALPHADAS(R) for Phase I Clinical Trials 2
(Date:4/1/2015)... 2015 San Francisco based sustainable medical ... medical charity, Operation Smile, have launched a ... Campaign Details: RxOrganics is generously donating 5% of ... Operation Smile throughout 2015. RxOrganics has committed to an ... that every order placed online through the Rxmedical shop ...
(Date:4/1/2015)... April 01, 2015 Results are in ... , which featured 11 new homes from across the ... that best utilized innovative building techniques and new technology ... Steven Winter Associates, Inc. (SWA) provided sustainability consulting services ... year’s challenge, including the first- and third-place winners. , ...
(Date:4/1/2015)... 01, 2015 Poisonous plants (poison ivy, ... change in recent years, increasing significantly in number and ... if exposed to poison plants (according to the American ... prepare for summer adventures in nature, they should be ... reaction is greater than ever. This year, Ivarest adds ...
(Date:3/31/2015)... Bon Secours New York Health System ... Nursing Care Center family last week. The Sisters formerly ... Yonkers which is scheduled to close later this year. ... the Sisters of Charity of New York, the decision ... place their Sisters at Schervier Nursing Care Center followed ...
(Date:3/31/2015)... As the demand for optimized mobile content ... a mobile-friendly website online sometime during the month of ... continued commitment to bring the best and most accurate ... the same great fitness information at http://www.chunkfitness.com ... to read while browsing on a mobile device. , ...
Breaking Medicine News(10 mins):Health News:RxOrganics Forges Unique Partnership to Bring More Smiles to Underserved Global Heath Communities 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 2Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 3Health News:Steven Winter Associates’ Projects Receive Top Honors in CT Zero Energy Challenge 4Health News:New Ivarest Poison Ivy Itch Spray Provides All-Day Comfort 2Health News:Bon Secours New York Health System Welcomes Retired Sisters of Charity to the Family 2
... By gluing together cells from different genomes to form mixed ... monkeys. In the report published online and in ... the monkeys, who are made up of as many as ... implanting these genetically mixed rhesus monkey embryos into mothers, the ...
... (HealthDay News) -- Researchers may have pinpointed how heart disease ... new preventive treatments. The team at Chiba University in ... protein called p53, resulting in inflammation in fat tissue, systemic ... effect is outlined in a study in the January issue ...
... News) -- Worried about the growing threat of ... Administration on Wednesday curbed the use of certain antibiotics ... antibiotics in food-producing animals is thought to be a ... The new ban includes antibiotics known as cephalosporins, ...
... trial found that rilonacept, an inhibitor of the ... that occur when initiating uric acid-lowering therapy. Results ... targeted therapy in prevention of gout flaresshow rilonacept ... infections or treatment-related serious adverse events reported. Full ...
... , WEDNESDAY, Jan. 4 (HealthDay News) -- People ... their current actions are more likely to be aggressive when ... on the here and now, without thinking about the impact ... are sober, but the effect is magnified greatly when they,re ...
... HealthDay Reporter , WEDNESDAY, Jan. 4 (HealthDay News) -- The ... by 76 percent since 1980, government health officials reported Wednesday. ... treatments that make it easier for older women to conceive, ... Disease Control and Prevention. "The growth in twin birth ...
Cached Medicine News:Health News:Scientists Create First Monkeys With Mixed Genomes 2Health News:FDA Curbs Use of Certain Antibiotics in Livestock, Poultry 2Health News:FDA Curbs Use of Certain Antibiotics in Livestock, Poultry 3Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 2Health News:Clinical trial demonstrates that rilonacept significantly reduces gout flares 3Health News:Study Reveals Who's More Prone to Be a 'Mean Drunk' 2Health News:U.S. Twin Births Soar: CDC 2Health News:U.S. Twin Births Soar: CDC 3
4 mm blade. Bayonet. Flat handle....
1 mm diameter. Angled 33 degrees. Round handle....
5 mm curved blade. Round handle....
0.75 mm diameter blade. Angled 60 degrees. Round handle. Designated most popular model or size....
Medicine Products: